Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series

08 May 2026 : Case report USA

Unknown etiology, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Adverse events of drug therapy

Madhu Parna Chakrabarti

^{ABCDEF 1*}, Steven Han

^{BDE 2}, Natasha M. Campbell^{ACDE 2}

DOI: 10.12659/AJCR.952158

Am J Case Rep 2026; 27:e952158

Authors information Article notes Copyright and License information

Introduction Case Reports Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Temporal relationship of allodynia with time and dose of tirzepatide.

Time (month)	Drug, dose	Symptoms	Management	Outcome

0	Tirzepatide, 2.5 mg	None	None	N/A
2	Tirzepatide titrated to 7.5 mg	Mild constipation	None	N/A
5	Tirzepatide, 7.5 mg	Mild fatigue, moderate allodynia	None	Allodynia persisted, patient continued tirzepatide
7	Tirzepatide, 7.5 mg	Moderate allodynia	Tirzepatide discontinued	Allodynia resolved

0	Semaglutide titrated to 14 mg	None	Semaglutide discontinued	Slow weight loss
3	Tirzepatide, 2.5 mg	None	None	N/A
8	Tirzepatide titrated to 12.5 mg	None	None	N/A
10	Tirzepatide, 15 mg	Severe allodynia, transient freezing sensation	Diphenhydramine	Symptoms subsided

Back to the Article